Machine learning based characterization of high risk carriers of HTLV-1-associated myelopathy (HAM)

Abstract HTLV-1-associated myelopathy (HAM) develops in a part of HTLV-1-infected individuals while most of the individuals remain asymptomatic. This complicates the identification of HTLV-1 carriers at elevated risk. In this study, we integrated HTLV-1 proviral load and antibody titers against Tax,...

Full description

Saved in:
Bibliographic Details
Main Authors: Md Ishtiak Rashid, Junya Sunagawa, Akari Matsuki, Asami Yamada, Toshiki Watanabe, Masako Iwanaga, Ki-Ryang Koh, Takafumi Shichijo, Masao Matsuoka, Jun-ichirou Yasunaga, Shinji Nakaoka
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-025-09635-2
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract HTLV-1-associated myelopathy (HAM) develops in a part of HTLV-1-infected individuals while most of the individuals remain asymptomatic. This complicates the identification of HTLV-1 carriers at elevated risk. In this study, we integrated HTLV-1 proviral load and antibody titers against Tax, Env, Gag p15, p19, and p24 proteins in a machine learning (ML) framework to identify and characterize high-risk individuals likely to develop HAM. We stratified asymptomatic carrier samples employing an anomaly detection model. We further developed and validated classifier models capable of distinguishing three clinical subgroups, carrier, ATL, and HAM for assessing the anomaly carrier samples as unseen test data. With most anomaly carrier samples (~ 76.47%) predicted as HAM, further statistical and interpretative analysis revealed the ‘HAM-like’ characteristics of the anomaly carrier samples indicating elevated risk. Additionally, significant heterogeneity in immune response was observed among other asymptomatic carriers. As an exploratory, hypothesis-generating study, our findings are preliminary and aim to propose potential biomarkers and computational strategies that warrant validation in future longitudinal investigations. Our machine learning-based approach offers a novel and insightful tool for identifying and evaluating high-risk characteristics for HAM, providing a holistic view of the complex immune dynamics of asymptomatic carriers of HTLV-1.
ISSN:2045-2322